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Abstract 
Health-care professionals, patients, and families seek as much information as possible about 
prognosis for patients with Alzheimer’s disease (AD); however we do not yet have a robust 
understanding of how demographic factors predict prognosis. We evaluated associations between 
age at presentation, age of onset and symptom length with cognitive decline as measured using the 
mini-mental state examination (MMSE) and clinical dementia rating sum-of-boxes (CDR-SOB) in a 
large dataset of AD patients. Age at presentation was associated with post-presentation decline in 
MMSE (p<0.001), with younger patients showing faster decline. There was little evidence of an 
association with change in CDR-SOB. Symptom length, rather than age, was the strongest predictor 
of MMSE and CDR-SOB at presentation, with increasing symptom length associated with worse 
outcomes. The evidence that younger AD patients have a more aggressive disease course implies 
that early diagnosis is essential.     
Keywords: Age Factors; Alzheimer Disease; cognition; age of onset; cognitive decline  
 
1. Introduction 
Dementia is a syndrome affecting more than 35 million people worldwide, with numbers predicted 
to increase to more than 65 million by 2030 [1]. Alzheimer’s disease (AD) is the commonest cause of 
dementia. Understanding the extent to which AD disease severity and progression vary with the age 
of the patient is important. Elucidating age-related associations not only aids understanding of the 
disease, but also allows clinicians and patients to have more precise and accurate information 
regarding prognosis.  
There is a suggestion that younger onset AD or all-cause dementia patients have a higher rate of 
disease progression measured using neuropsychological test changes over time [2-5].  However, 
3 
 
severity at clinical assessment varies, with most studies showing no association with age and three 
reporting worse cognition in younger cases compared with older cases [6-8].  
Different age variables (age at presentation, at diagnosis, at symptom onset, at cognitive decline) 
can be used in studies investigating associations between age and disease progression, presenting 
challenges both when designing studies and when performing statistical analysis. Age at 
presentation and/or age at diagnosis are usually accurately recorded in prospective studies, whilst 
ages at symptom onset (age at decline) is often based on patient or caregiver’s recall in discussion 
with a clinician. Clinical associations with each of these various ages can potentially be different, 
particularly if symptom length (which can be expressed as time from symptom onset to either age at 
presentation or age at diagnosis) is a strong predictor of disease progression. Additionally, 
interpretation of each of these age associations is changed if symptom length is used as a covariate 
in the analysis.  
In the dataset used in this study, age at presentation and recalled age at onset (age at decline) were 
available. Symptom length was computed as the difference between these ages. Our primary aim 
was to investigate the associations between these variables (age of onset, presentation and 
symptom length) and disease progression (change in cognitive scores) over time. Our secondary aim 
was to understand whether similar associations were found with disease severity (cognitive status 
scores) at presentation. We hypothesized that younger age of presentation or onset would be 
associated with greater decline in cognitive status scores.  
 
2. Materials and Methods 
2.1.  Subjects 
We used data from AD patients collected by the National Alzheimer’s Coordinating Center (NACC, 
n=7154). NACC developed and maintains a database of standardized clinical research data from 
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individuals with normal cognition, mild cognitive impairment and degenerative diseases collected 
from 34 past and present NIA-funded ADCs from across the USA. The study was approved by an 
institutional review board at each institution and is in line with the Helsinki Declaration of 1975. 
NACC recruitment and data collection has been described previously [9]. Data included patients seen 
at ADCs from the beginning of data collection in 2005 and June 2012. Subjects included in our study 
had to have dementia and a diagnosis of probable or possible AD according to standard diagnostic 
criteria [10] at first NACC visit.  We only included subjects who had a recorded age of onset, mini-
mental state examination (MMSE) at baseline and educational attainment.  Notably, only a subset of 
subjects had follow-up visits (approximately half) and so progression of disease was only measurable 
in these subjects.  
 
2.2. Variables  
We used the following variables in our analyses: age at first NACC clinic presentation, age of onset 
(age of decline) defined as a clinician’s estimate of the age at which cognitive decline began (prior to 
NACC presentation), length of symptoms (calculated as age of first NACC clinic presentation minus 
age of onset), ADC, MMSE, clinical dementia rating sum-of-boxes (CDR-SOB), gender, years of 
education, first predominant cognitive symptom and apolipoprotein E (APOE) ε4 genotype.  
The timing of collection of variables was as follows: age at presentation was the age of the patient at 
first NACC visit; NACC visits can sometimes follow an initial clinical assessment visit either at an ADC 
or another center dependent on each center’s recruitment practice. Age of onset and first 
predominant cognitive symptom was recorded at first visit by the clinician. First predominant 
cognitive symptom was based on the clinician’s opinion following discussion with the patient and 
caregiver and review of the cognitive profile.  Testing for cross-sectional MMSE and CDR-SOB scores 
occurred at the first NACC visit. The longitudinal annualized differences in MMSE and CDR-SOB 
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scores were calculated from the difference between scores recorded at first and second visits for 
those subjects with follow up.  
MMSE and CDR sum of boxes at first NACC visit were used as measures of cognitive status. ADC was 
included as a covariate in all analyses to attempt to allow for the fact that there may be variation in 
the recording of age of onset across centers [11] or scheduling of patients for first NACC visit. 
Gender and years of education were used in analyses of cognitive status variables to allow for 
differences in scores attributable to these potential confounders. We excluded subjects from the 
longitudinal analyses who had an interval of <180 days between their first two visits in order to 
minimize practice effects. Notably, some subjects who had a repeat CDR-SOB did not have a repeat 
MMSE and therefore numbers of subjects included varied between these analyses. Since change in 
cognitive status scores over time might be related to baseline score, we included baseline score as a 
covariate in these longitudinal analyses. 
2.3. Statistical analysis 
In order to examine whether the age of onset or that at presentation, or the difference between the 
two (symptom length), was most important we first separately assessed these before then fitting a 
model with both age of presentation and symptom length as predictors (age at onset then being 
omitted as it can be derived from the other two). To investigate potential non-linear associations 
between the variables investigated, we used generalized additive models using the gam function in 
the mgcv package in R. These permit flexible estimation and testing of non-linear associations [12].  
For longitudinal analyses separate generalized additive regression models relating annualized 
change in MMSE score to each of i) age at presentation, ii) age of onset and iii) symptom length were 
fitted. The associations of these ages and symptom length variables with change in MMSE were 
modelled non-linearly using default thin plate regression splines, with the smoothing parameter 
estimated using generalized cross-validation. Models including both age at presentation and 
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symptom length as covariates were also fitted. Gender and years of education were included as 
linear covariates, and MMSE score at the first NACC visit was included non-linearly using a thin plate 
spline. Random ADC effects were included for all models. Analogous models for the annualised CDR-
SOB change, with gender, years of education and the CDR-SOB score at the first NACC visit as 
covariates were also fitted. To aid interpretation of differences between younger and older onset 
cases, similar analyses using a binary <65 years vs ≥65 years age at presentation cut-off were also 
fitted. Further models with change in MMSE as the outcome variable were fitted in subjects who 
performed above floor (0) at first and second NACC visit, and again re-fitted in subjects who had a 
first NACC visit score of >9, to assess whether results were influenced by those who fall to floor or 
who were severe at baseline. Similarly, we fitted further CDR change models excluding those who 
were at floor (18) at either first NACC visit and second NACC visit and then again excluding those 
with a first NACC visit score >14. These cut-off scores for MMSE and CDR-SOB are arbitrary but 
should reduce the chances of results being materially influenced by those whose score reductions 
are less than they would be were there no floor effects.  
Similarly, for cross-sectional analyses separate generalized additive regression models relating each 
of first visit MMSE score and first visit CDR-SOB to each of i) age at presentation, ii) age of onset and 
iii) symptom length were fitted. Models including both age at presentation and symptom length as 
predictors were also fitted. Gender and years of education (linearly) were included in all these 
models. Again, additional models were also fitted with age at presentation, dichotomized at 65 
years, to assess differences between older and younger presenting cases.  
To assess whether our results were affected by disease presentation, as this has been shown to be 
associated with age of presentation [13],  we refitted all models adjusting additionally for first 
cognitive symptom where this was known (categories: memory; judgment and problem solving; 
language; visuospatial function; attention/concentration; “other”; fluctuating cognition; no 
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symptom). Similarly we refitted all models adjusting for APOE ε4 status in the subset of patients in 
which this was tested.  
For the results of all analyses plots showing predicted values of each dependent variable against 
either age at presentation or symptom length are shown. Predictions are for individuals with values 
of other covariates that are typical of those in the dataset, and with the ADC (mean zero) random 
effect set to zero. The plots include 95% pointwise confidence intervals and p-values testing the null 
hypothesis that age at presentation or symptom length has no independent association with the 
dependent variable are provided. We note that as described by Wood [12], both the confidence 
intervals and p-values are approximate, since their derivations ignore uncertainty induced through 
selection of the smoothing parameter. 
3. Results 
Summary demographic information for the group is reported in Table 1.  7154 subjects were 
included in the cross-sectional analysis and were on average 75 years old when presenting for their 
first NACC visit and ranged in age at presentation between 36 and 104 years and age at onset 
between 20 and 103 years. Slightly more than half were female and subjects were typically mild-to-
moderately demented with MMSE scores around 19 out of 30. The subset with longitudinal data 
(n=3960) were not markedly different from the cross-sectional dataset. 
 Cross-sectional dataset Longitudinal dataset  
N 7154 3960 
N Alzheimer Disease Centers 33 31 
Age at first presentation, years 75.5 (9.6) 75.1 (9.5) 
Age at onset, years 70.7 (9.7) 70.2 (9.6) 
Symptom length, years 4.8 (3.4) 4.8 (3.3) 
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Gender % women 55.9 53.1 
N Probable AD (%)  5953 (83.2) 3353 (84.7) 
Education, years  13.9 (3.8) 14.2 (3.7) 
MMSE at first presentation, /30 19.4 (6.8) 20.5 (6.1) 
MMSE at second presentation, /30 ^ N/A 18.4 (7.0)  
CDR SOB at first presentation, /18  6.7 (4.1) 6.1 (3.7) 
CDR SOB at second presentation, /18 N/A 7.8 (4.4) 
Interval between visits 1 and 2 for MMSE, days 
^ 
N/A 425.0 (137.9) 
Annualised change in MMSE (points/year) ^ N/A -2.1 (3.6) 
Interval between visits 1 and 2 for CDR sum of 
boxes, days  
N/A 427.2 (141.7) 
Annualised change in CDR sum of boxes 
(points/year) 
N/A 1.5 (2.3) 
First 
predominant 
cognitive 
symptom % # 
Memory  89.2 90.1 
Judgment and problem 
solving 
3.6 3.1 
Language 4.0 3.7 
Visuospatial function 2.2 2.3 
Attention / concentration 0.6 0.5 
“Other” 0.4 0.4 
Fluctuating cognition 0.1 0.0 
No symptom 0.0 0.0 
APOE ε4 status %0, 1, 2 alleles ¥ 42.2, 45.4, 12.4 41.6, 45.7, 12.7 
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Table 1 Summary demographics and cognitive status scores for cross-sectional and longitudinal 
analyses. Mean (SD) unless otherwise stated. 
^ data available in 3816; # data available in 7134 for cross-sectional analysis and 3955 for 
longitudinal; ¥ data available in 4885 for cross-sectional analysis and 3052 for longitudinal; N/A - not 
applicable  
Figures 1a-c illustrate the estimated relationships between rates of change in MMSE between NACC 
visits 1 and 2 and ages of presentation and onset and symptom length. The predictions and 
confidence intervals shown relate specifically to a female with 14 years of education, an MMSE at 
presentation of 20, from an ADC with random effect equal to zero; altering one or more of these 
choices will change all of the predictions by a constant amount, but leave the form of the 
relationship unchanged. There was strong evidence (p<0.001) that the rate of change (adjusted for 
sex, years of education and baseline MMSE) depends on age at presentation with the greatest rates 
of decline seen at younger ages. The rates of decline decrease with increasing age up to around age 
80, then appear to plateau. There was no evidence that symptom length was related to the rate of 
change in MMSE when considered alone (p=0.11) or after adjustment for age at presentation 
(p=0.29, figure 1e). As a consequence of this, the association with age of onset was similar to that 
with age of presentation (p<0.001) and adjustment for symptom length had little impact on the 
association with age at presentation (figure 1d). Coefficients of gender and (linear) education are 
shown in supplementary table 1 for these models assessing ages and symptom length as continuous 
variables. From the model where age at presentation was dichotomized it was estimated that after 
adjustment for symptom length, gender, education, baseline MMSE and ADC, those presenting 
below the age of 65 years declined by 0.69 (95% CI 0.37 to 1.02, p<0.001) points per year more than 
those presenting at age 65 or above. 
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From analogous models for rates of change in CDR-SOB there was borderline statistically significant 
evidence of an association (adjusted for sex, years of education and baseline CDR-SOB) between age 
at presentation and rate of change in CDR-SOB (p=0.05, and p=0.03 with additional adjustment for 
symptom length). The observed relationship was approximately “u”-shaped in form with the 
youngest and oldest presenting cases having the largest rates of change. There was no evidence of 
an association between CDR-SOB change and age at onset (p=0.16) or symptom length (p=0.43). 
From the dichotomized model, after adjustment for symptom length, gender, education, baseline 
CDR-SOB and ADC, there was no evidence (p=0.92) that change in CDR-SOB differed between those 
presenting below the age of 65 and those presenting at age 65 or above. 
  
1a  
 
2a  
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Figure 1. Plots of predicted change in MMSE (points per year) with 95% pointwise confidence 
intervals with predictors being: a) age of presentation, b) age of onset, c) symptom length, d) age 
of presentation adjusted for symptom length and e) symptom length adjusted for age of 
presentation.  Predictions are for a female subject, with 14 years of education, and a MMSE at 
presentation of 20. In plot d) the prediction is for a patient with symptom length 5 years. In plot e) 
the prediction is for a patient with age of presentation 75 years. 
Figure 2. Plots of the predicted change in CDR-SOB (points per year) with 95% pointwise 
confidence intervals with predictors being: a) age of presentation b) age of onset, c) symptom 
length, d) age of presentation adjusted for symptom length and e) symptom length adjusted for 
age of presentation.  Predictions are for a female subject, with 14 years of education, and a CDR-
SOB at presentation of 7. In plot d) the prediction is for a patient with symptom length 5 years. In 
plot e) the prediction is for a patient with age of presentation 75 years. 
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Figures 3a-c show the relationships between MMSE at first visit and age of presentation, onset and 
symptom length. The predictions and confidence intervals shown relate specifically to a female with 
14 years of education and ADC random effect equal to zero; as above altering one or both of these 
choices will change all of the predictions by a constant amount, but leave the form of the 
relationship unchanged. Figures 3d and 3e show the mutually adjusted associations with age at 
presentation and symptom length. There was evidence of an association between age at 
presentation and MMSE when analyzed in the separate model with the relationship a shallow 
inverted “u” (figure 3a, p<0.001). There was a positive relationship between age of onset and MMSE 
(figure 3b, p<0.001). The relationship between symptom length and MMSE was “u” shaped, 
although the predictions of MMSE for large symptom lengths were imprecise due to the limited 
number of patients with such long symptom lengths (figure 3c, p<0.001). The co-adjusted 
relationships between age of presentation and symptom length with MMSE at baseline remained 
significant and similar in form (figures 3d and 3e, both p<0.001). Coefficients for the effects of 
gender and education for these models where ages and symptom length are analysed as continuous 
variables are shown in supplementary table 1. From the model where age at presentation was 
dichotomised it was estimated that after adjustment for symptom length, gender, education and 
ADC, those with an age at presentation of 65 years or above had a mean MMSE at first visit 1.37 
(95% CI 0.95 to 1.78, p<0.001) points higher than those presenting below 65 years. 
There was evidence of an association between age at presentation and CDR-SOB (see Figure 4a, 
p<0.001); little relationship was discernable until 70 years from which point an older age of 
presentation was associated with poorer scores. There was a small association of age of onset with 
CDR-SOB, with older ages associated with better scores (see figure 4b, p=0.02). Symptom length 
showed an inverted “u” shaped relationship with CDR-SOB (see figure 4c, p<0.001). The associations 
between CDR-SOB with age at presentation and symptom length in the co-adjusted model remained 
significant (figures 4d and 4e, p<0.001 both tests), with their independent associations remaining 
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largely unchanged. From the dichotomised model, after adjustment for symptom length, gender, 
education and ADC, those presenting at 65 years and above had CDR-SOB at first visit 0.11 lower 
(95% CI -0.14 to 0.35, p=0.40). 
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Figure 3. Plots of predicted MMSE at first visit with 95% pointwise confidence intervals with 
predictors being: a) age of presentation, b) age of onset, c) symptom length, d) age of presentation 
adjusted for symptom length and e) symptom length adjusted for age of presentation.  Predictions 
are for a female subject with 14 years of education. In plot d) the prediction is for a patient with 
symptom length 5 years. In plot e) the prediction is for a patient with age of presentation 75 years. 
Figure 4. Plots of predicted CDR-SOB at first visit with 95% pointwise confidence intervals with 
predictors being: a) age of presentation, b) age of onset, c) symptom length, d) age of presentation 
adjusted for symptom length and e) symptom length adjusted for age of presentation.  Predictions 
are for a female subject with 14 years of education. In plot d) the prediction is for a patient with 
symptom length 5 years. In plot e) the prediction is for a patient with age of presentation 75 years. 
Adjusting for APOE ε4 meant that the relationship between symptom length and MMSE change 
became borderline significant in the separate model (p=0.03, see supplementary figure 1); this 
relationship was not significant when additionally adjusting for age of presentation (p=0.09). For 
CDR-SOB change, excluding those who scored at floor at either timepoint or those who scored >14 
at baseline or adjusting for APOE ε4 meant the borderline significant result between age of 
presentation and score change became non statistically significant in individual models (p>0.05, all 
tests) as well as the model for APOE ε4 additionally adjusted for symptom length (p=0.3). In all other 
analyses where poor performers were excluded or models were adjusted for APOE ε4 or first 
predominant cognitive symptom, results did not materially change.   
 
4. Discussion  
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We found strong evidence that the AD subjects who presented at younger ages subsequently 
progressed faster with respect to MMSE. For CDR-SOB, those who presented at younger ages 
progressed more quickly, as did those at the oldest ages; across the middle of the age range the 
relationship appeared quite flat.  There was no evidence that symptom length was associated with 
MMSE or CDR-SOB progression with or without adjustment for age at presentation. Little influence 
of gender was seen in these longitudinal analyses; higher educational attainment was associated 
with greater cognitive decline (supplementary table 1).  
Analysis of first visit results revealed that increased age at presentation was associated with better 
MMSE scores up to about 70 years. From 70 years an increase in age was associated with both 
poorer MMSE and CDR scores. Symptom length had a strong relationship with both MMSE and CDR-
SOB with a longer symptom length (up to 20 years) associated with poorer scores. In the co-adjusted 
models a higher age of presentation was associated with better scores on both tests until 70 years. 
From that point an increase in age was associated with poorer scores. A higher age of onset was 
associated with better MMSE and CDR scores. The differing forms of the relationships with age at 
presentation and age at onset are linked to the effect of symptom length. The down turn in the 
association with age at presentation at older ages being a reflection of the fact that those with the 
oldest presentations are likely to have long symptom lengths (associated with worse outcomes) 
despite their likely late age at onset (associated more weakly with better outcomes).   Women 
tended to perform more poorly than men on MMSE and CDR-SOB allowing for educational 
attainment; greater education was associated with better baseline cognitive performance 
(supplementary table 1).  
Longitudinal results show earlier-presenting AD cases are associated with more aggressive disease 
progression. Longitudinal CDR-SOB results also suggest that later presenting cases from the 10th 
decade onwards may experience more aggressive disease progression. This latter association may be 
due to fact that older patients are more likely to be frail and have comorbid conditions which are 
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associated with more rapid decline. Cross-sectional results are more complicated with increased 
symptom length (up to around 15 years) being a predictor of poorer cognitive status at baseline. 
Earlier age of presentation before 70 years and later age after 70 years was associated with more 
severe disease at baseline. The effect prior to 70 may again be explained by a more aggressive 
disease at earlier ages. The effect after 70 years may be in part due to bias: older patients are more 
likely to have memory deficits (at least at first) and older patients may expect memory to decline 
with age and therefore it may take them longer to seek help and obtain an appointment. The fact 
that higher educational attainment was associated with greater decline (see supplementary table 1), 
but better cognitive status at baseline, may be related to increased cognitive reserve in those with 
more education [14].  
Other biases are important to consider when interpreting these results, in particular inaccuracies in 
recording of ages at presentation and symptom length. There will be inaccuracy in symptom length 
due to inaccurate recall of age of onset [11]. Additionally, if some patients have appointments 
postponed and others do not, or if some patients have easier access to medical care whilst others do 
not, then this will impact on with age at presentation. It is plausible that at least some of the 
between-subject variability in ages at presentation and symptom lengths will be due to factors 
unrelated to the disease and so these effects will be akin to those induced by random measurement 
error in predictor variables in regression models. It is known that such measurement error induces 
bias [15]: in simple linear regression models the true effect is always attenuated (hence the bias is 
sometimes termed regression dilution bias [16]), but in multiple regression models this need not be 
the case. Here, where errors due to presentation variability and inaccurate recall variability are likely 
to have different magnitudes it is difficult to anticipate the impact. This means that associations of 
small magnitude in particular need to be interpreted cautiously.  
Previously only relatively small and often single-site studies have investigated relationships between 
age and features of AD such as progression and cognitive status. Different definitions of symptom 
19 
 
length, age of onset and age of presentation have been used across studies and the age variable 
used in analyses to dichotomize subjects or used as a continuous predictor varies also. The type and 
structure of healthcare systems from which patient data are derived may also influence results. Our 
results presented here may indicate that studies assessing change in cognitive status score are more 
robust to the choice of age variable used as a predictor compared with those assessing relationships 
between baseline cognitive status and age. We also found that associations of scores with age and 
symptom length are largely non-linear. This means that the range of ages included in studies as well 
as the distribution of ages will affect associations seen.  
A number of studies have found evidence using serial neuropsychology that the rate of progression 
decreased with increased age of symptom onset or age at assessment [2-4,17-22]. One study 
reported older age to be associated with greater decline [23]. One early study showed rate of 
progression in a dementia ratings scale to be higher in older onset cases [24].  
Two studies have found that longer symptom lengths are associated with poorer cognitive function 
at assessment [18,22]. A number of studies have found no evidence of a relationship between 
MMSE (including modified versions) and age of symptom onset, disease onset, caregiver-noted 
substantive change, or diagnosis [3,5,25-31]; whereas others found lower MMSE at first time-point 
in younger diagnosed, assessed or symptom onset cases [6-8], in keeping with our own findings. Two 
studies of the same patients reported CDR-SOB and found no evidence of a difference according to 
age of symptom onset [19,28]. All of these studies either dichotomized subjects, placed them into 
tertiles or performed linear analyses. The nature of the relationships we found between 
presentation age and cognitive scores may partly explain the apparent discrepancies amongst the 
literature, particularly if different ranges and distributions of ages are included.   
Imaging studies have demonstrated that AD or mild cognitive impairment patients who progress to 
AD have lower rates of tissue loss at older ages [32,33]. Further, another study has revealed younger 
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cases having greater progressive cortical thinning in association cortices, whereas only a small area 
of the medial temporal lobe was thinning more quickly in older cases [19]. In addition, increased 
subcortical structural decline has been demonstrated in younger as opposed to older cases [28]. EEG 
analysis has demonstrated that younger cases have more severe slowing of spontaneous oscillatory 
activity than older cases [31] as well as more common focal and diffuse EEG abnormalities [7].  
Cerebrospinal fluid analysis has also demonstrated younger cases having more amyloid pathology 
(as well as being more severe according to MMSE) [6]. These findings together with our own provide 
multiple lines of evidence of a differing and more aggressive course in younger onset patients. 
Interestingly, results did not greatly change when adjusting for APOE ε4. Since APOE ε4 is not only 
associated with greater risk of AD but also with earlier age of onset, this means there are likely other 
genes or variables which are associated with earlier age of onset and increased rate of decline.  
These other variables might be co-morbidities [34] and/or identified risk factors such as low 
education in early life, hypertension and obesity in midlife or smoking, depression or social isolation 
in late life [35].  Other predictors, such as subtle atrophy patterns in the posterior of the brain, may 
also indicate faster decline [36]. Clinically, this means that younger onset patients would benefit 
from early diagnosis, in order that they gain key prognostic information and can make appropriate 
plans, before they become severely affected.  
The major strengths of this study are the multi-site and systematic nature of data collection, 
combined with the assessment of two commonly used methods to assess cognitive status (CDR and 
MMSE). One limitation with this study is that we only had evidence for change in cognitive status 
measures in a subset of the subjects owing to the nature of the clinical data collection.  It may be 
that those subjects with second NACC visit neuropsychology are different to those who are not 
followed, which may bias results if the probability of having a second visit is related to change in 
cognitive status score. Other work using linear regression models has shown that changes in scores 
such as MMSE are variable amongst AD patients; 95% of patients have changes between -7.15 and 
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+0.33 points per year and with test-retest differences over a 1 month interval ranging from  +7 
points to -8 points. This means that on an individual level, MMSE may not be appropriate to track 
changes in cognition, particularly over short intervals [23]. Other cognitive tests are available from 
NACC [9]. We did not investigate the effects of both age variables and symptom length on all tests 
available although this may be an avenue of future research.  Further we did not include 
neuropathological information in these subjects in order to be as inclusive as possible of the subjects 
seen at ADCs; it is possible that neuropathological data are biased towards more atypical cases of 
AD. In addition many of these patients may have presented earlier to a specialist, but then were 
referred to an ADC due to interest in research.  This procedure may differ across ADCs and be a 
source of noise in the dataset. However, we adjusted for ADC in our analyses and for symptom 
length, which should allow for some aspects of this confounding issue. This is also why we use the 
term “age at presentation” rather than “age at diagnosis”. NACC co-ordinates academic AD centers 
which may have more difficult and complex cases compared with community-based AD clinics, thus 
limiting generalizability of our findings to the wider AD population. Finally, using the analytical 
approach we chose, the derived confidence intervals understate uncertainty which may mean 
significance (p-values) is overstated.  
In summary, our study demonstrates in a large AD cohort that differences exist in disease course 
according to age at presentation and onset. We found the strongest predictor of progression was 
age rather than symptom length (younger age associated with quicker progression and therefore 
implying more aggressive disease) and that the strongest predictor of disease severity at first visit 
was symptom length rather than age (longer symptom length up to two decades associated with 
greater severity).  Understanding the course of Alzheimer’s disease and those variables that can 
influence this course is extremely important and may influence clinical services. The finding that 
younger AD patients have a more aggressive disease course implies that early diagnosis is essential.     
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Supplementary Section  
 
Supplementary figure 1: Plot of predicted change in MMSE (points per year) with 95% pointwise 
confidence intervals by symptom length.  Predictions are for a female subject, with 14 years of 
education, an MMSE at presentation of 20 and one APOE ε4 allele. 
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 Predictor(s) of 
interest in main 
results section, 
years 
Outcome  
MMSE  CDR 
Longitudinal 
analyses 
Age at presentation Gender: -0.12 
[0.12], p=0.3 
Education: -0.05 
[0.02], p=0.004 
Gender: 0.11[0.07], 
p=0.1  
Education: 0.02 
[0.01], p=0.02 
Age of onset Gender: -0.13 
[0.12], p=0.3 
Education: -0.05 
[0.02], p=0.004 
Gender: 0.12 
[0.07], p=0.1 
Education:  0.02 
[0.01], p=0.02 
Symptom length  Gender: -0.10 
[0.12], p=0.4 
Education: -0.06 
[0.02], p<0.001 
Gender: 0.12 
[0.07], p=0.1 
Education: 0.02 
[0.01], p=0.03 
Age at presentation 
and symptom 
length 
Gender: -0.11 
[0.12], p=0.4 
Education: -0.05 
[0.02], p=0.005 
Gender: 0.11 
[0.07], p=0.1 
Education: 0.02 
[0.01], p=0.03 
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Cross-sectional 
analyses  
Age at presentation Gender: -0.14 
[0.16], p=0.4 
Education: 0.34 
[0.02], p<0.001 
Gender: 0.20 
[0.10], p=0.04 
Education: -0.10 
[0.01], p<0.001 
Age of onset Gender: -0.20 
[0.16], p=0.2 
Education: 0.36 
[0.02], p<0.001 
Gender: 0.24 
[0.10], p=0.01 
Education: -0.12 
[0.01], p<0.001 
Symptom length  Gender: -0.34 
[0.15], p=0.02 
Education: 0.34 
[0.02], p<0.001 
Gender: 0.37 
[0.09], p<0.001 
Education: -0.12 
[0.01], p<0.001 
Age at presentation 
and symptom 
length 
Gender: -0.32 
[0.15], p=0.03 
Education: 0.35 
[0.02], p<0.001 
Gender:0.35 [0.09] 
p<0.001 
Education: -0.11 
[0.01], p<0.001 
 
Supplementary table 1  Results from mutually-adjusted models for the effects of gender and 
education on outcomes. Longitudinal models were additionally adjusted for cognitive status at first 
visit (either MMSE for MMSE change outcomes, or CDR-SOB for CDR-SOB change outcomes), and 
ADC. Cross-sectional models were adjusted for ADC. Coefficients represent change in the outcome 
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for a 1-unit increase in the predictor [standard error], p value. For gender this represents the 
difference seen in women, compared with men.  
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for a 1-unit increase in the predictor [standard error], p value. For gender this represents the 
difference seen in women, compared with men.  
 
 
 
